STRS Ohio’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.62M | Buy |
12,316
+9,996
| +431% | +$1.33M | 0.01% | 610 |
|
|
2025
Q4 | $329K | Buy |
2,320
+4
| +0.2% | +$579 | ﹤0.01% | 1282 |
|
|
2025
Q3 | $325K | Buy |
2,316
+1
| +0% | +$135 | ﹤0.01% | 1298 |
|
|
2025
Q2 | $291K | Buy |
+2,315
| New | +$265K | ﹤0.01% | 1519 |
|
|
2024
Q4 | – | Sell |
-16,569
| Closed | -$1.91M | – | 1987 |
|
|
2024
Q3 | $1.91M | Sell |
16,569
-4,493
| -21% | -$616K | 0.01% | 661 |
|
|
2024
Q2 | $2.9M | Buy |
21,062
+4,848
| +30% | +$665K | 0.01% | 518 |
|
|
2024
Q1 | $2.24M | Buy |
16,214
+1,357
| +9% | +$185K | 0.01% | 587 |
|
|
2023
Q4 | $1.96M | Buy |
+14,857
| New | +$1.71M | 0.01% | 609 |
|
|
2023
Q3 | – | Sell |
-17,341
| Closed | -$1.64M | – | 2011 |
|
|
2023
Q2 | $1.64M | Sell |
17,341
-1,828
| -10% | -$179K | 0.01% | 706 |
|
|
2023
Q1 | $1.94M | Buy |
19,169
+3,042
| +19% | +$317K | 0.01% | 643 |
|
|
2022
Q4 | $1.93M | Buy |
16,127
+3,047
| +23% | +$357K | 0.01% | 642 |
|
|
2022
Q3 | $1.39M | Buy |
13,080
+212
| +2% | +$21.5K | 0.01% | 729 |
|
|
2022
Q2 | $1.25M | Buy |
12,868
+11,878
| +1,200% | +$1.1M | 0.01% | 793 |
|
|
2022
Q1 | $92K | Hold |
990
| – | – | ﹤0.01% | 1860 |
|
|
2021
Q4 | $84K | Hold |
990
| – | – | ﹤0.01% | 1930 |
|
|
2021
Q3 | $94K | Hold |
990
| – | – | ﹤0.01% | 1954 |
|
|
2021
Q2 | $96K | Sell |
990
-8,224
| -89% | -$788K | ﹤0.01% | 1985 |
|
|
2021
Q1 | $896K | Sell |
9,214
-13,343
| -59% | -$1.4M | ﹤0.01% | 1234 |
|
|
2020
Q4 | $2.16M | Sell |
22,557
-854
| -4% | -$82.5K | 0.01% | 673 |
|
|
2020
Q3 | $2.25M | Sell |
23,411
-1,206
| -5% | -$140K | 0.01% | 605 |
|
|
2020
Q2 | $3M | Buy |
24,617
+17,038
| +225% | +$1.88M | 0.01% | 530 |
|
|
2020
Q1 | $655K | Buy |
7,579
+1,694
| +29% | +$166K | ﹤0.01% | 937 |
|
|
2019
Q4 | $632K | Buy |
+5,885
| New | +$616K | ﹤0.01% | 1282 |
|
|
2019
Q2 | – | Sell |
-1,808
| Closed | -$148K | – | 2173 |
|
|
2019
Q1 | $159K | Sell |
1,808
-859
| -32% | -$71.8K | ﹤0.01% | 1724 |
|
|
2018
Q4 | $190K | Buy |
2,667
+646
| +32% | +$61.9K | ﹤0.01% | 1646 |
|
|
2018
Q3 | $248K | Sell |
2,021
-165
| -8% | -$18.7K | ﹤0.01% | 1674 |
|
|
2018
Q2 | $214K | Buy |
+2,186
| New | +$196K | ﹤0.01% | 1725 |
|
|
2016
Q2 | – | Sell |
-18,800
| Closed | -$743K | – | 1980 |
|
|
2016
Q1 | $743K | Buy |
18,800
+1,400
| +8% | +$55.6K | ﹤0.01% | 958 |
|
|
2015
Q4 | $984K | Buy |
17,400
+3,100
| +22% | +$158K | ﹤0.01% | 817 |
|
|
2015
Q3 | $568K | Sell |
14,300
-25,800
| -64% | -$1.25M | ﹤0.01% | 1217 |
|
|
2015
Q2 | $1.92M | Sell |
40,100
-4,100
| -9% | -$174K | 0.01% | 633 |
|
|
2015
Q1 | $1.75M | Sell |
44,200
-10,300
| -19% | -$368K | 0.01% | 625 |
|
|
2014
Q4 | $1.22M | Sell |
54,500
-7,100
| -12% | -$135K | 0.01% | 706 |
|
|
2014
Q3 | $965K | Buy |
61,600
+26,600
| +76% | +$398K | ﹤0.01% | 776 |
|
|
2014
Q2 | $519K | Buy |
35,000
+2,400
| +7% | +$33.9K | ﹤0.01% | 1214 |
|
|
2014
Q1 | $525K | Buy |
+32,600
| New | +$558K | ﹤0.01% | 1140 |
|
Other funds holding NBIX
VPM
VCM
STRS Ohio's NBIX Position: Q1 2026 in Review
STRS Ohio increased its Neurocrine Biosciences (NBIX) stake by 431% in Q1 2026, buying an estimated $1.33M and bringing the position to 12,316 shares worth $1.62M. The position accounts for 0.01% of the portfolio, ranked #610.
STRS Ohio first reported a position in NBIX in Q1 2014 and has held it in 36 quarters since. The position peaked at $3M in Q2 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- STRS Ohio held 12,316 shares of Neurocrine Biosciences worth $1.62M as of Q1 2026.
- STRS Ohio bought 9,996 Neurocrine Biosciences shares in Q1 2026, an estimated $1.33M.
- Neurocrine Biosciences made up 0.01% of STRS Ohio's portfolio in Q1 2026, its #610 holding.
- STRS Ohio first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 36 quarters since.
- STRS Ohio's Neurocrine Biosciences position peaked at $3M in Q2 2020.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on STRS Ohio's 13F filing for Q1 2026, filed 24 Apr 2026.